Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
VYNE Therapeutics ( (VYNE) ) just unveiled an announcement.
VYNE Therapeutics’ stockholders approved an amendment to the 2023 Equity Incentive Plan, increasing shares available for issuance and adjusting share recycling policies. During the annual meeting, all five proposals, including director elections and executive compensation, were approved, indicating strong shareholder support and potential for strategic growth.
More about VYNE Therapeutics
VYNE Therapeutics Inc. operates within the pharmaceutical industry, focusing on developing and commercializing therapies for dermatological conditions and other medical needs.
YTD Price Performance: 9.44%
Average Trading Volume: 84,606
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $37.62M
Find detailed analytics on VYNE stock on TipRanks’ Stock Analysis page.